Introduction
============

Doxorubicin (DOX), is a naturally occurring anthracycline and widely used for the treatment of a range of human malignancies including hematomas and solid tumors (Elbaky et al., 2010\[[@R8]\]). The use of doxorubicin has been associated with severe toxic effects and most dangerous one is the dose-dependent cardiotoxicity, leading to cardiomyopathy and eventually congestive heart failure. Cardiotoxicity includes a wide range of cardiac effects from small changes in blood pressure and arrhythmias to cardiomyopathy (Schimmel et al., 2004\[[@R35]\]).

Acute DOX cardiotoxicity occurs within 2-3 days of its administration. Studies have shown that DOX causes cardiotoxicity through mechanisms other than those mediating its antitumor effect (Khan et al., 2014\[[@R19]\]). However, it appears that the induction of an oxidative stress within myocardial tissue constitutes a common denominator (Vergely et al., 2007\[[@R42]\]). It is usually arbitrated through lipid peroxidation and inhibition of long fatty acid oxidation in cardiac tissues. The oxidative stress, lipid peroxidation and mitochondrial dysfunction have been associated with DOX-induced cardiomyopathy (Nohl et al., 1998\[[@R33]\]).

DOX generates reactive oxygen species (ROS) via several mechanisms (Malisza and Hasinoff, 1995\[[@R27]\]) and can directly form complexes with ferrous ion within the cell. These complexes are pertinent to generate ROS in the presence or the absence of reducing components (Vergely et al., 2007\[[@R42]\]). The investigations showed that animals treated with compounds of antioxidant potential protects heart against DOX induced toxicity (Nazeyrollas et al., 1999\[[@R31]\]; Liu et al., 2002\[[@R23]\]). Unani System of Medicine offers a number of cardioprotective and cardiotonic single and compound drugs which have been mentioned by ancient renowned Unani physicians in classical literatures including *Khameera Abresham Sada, Khameera Gaozabansada, Khameera Abresham Uood Mastagi Wala* etc (Ahmad et al., 2010\[[@R3]\]). Scientific studies have proven the cardioprotective effect of some Unani compound formulations such as Khameera*Abresham Hakeem Arshad Wala* (KAHAW) (Goyal et al., 2010\[[@R10]\]), *Khamira Abresham Uood Mastigi Wala* (KAUM), *Khamira Abresham Sada* (KAS) etc (Kabeer, 1951\[[@R17]\]), which are used by Unani Physicians since ancient times.

Abresham, a cocoon of *Bombyx mori* (silkworm) is the main ingredient of KAHAW, KAUM and KAS. Therefore, it was thought worthwhile to carry out scientific validation of cardioprotective potential of Abresham. The two main constituents of abresham are fibroin (70 %) and sericin (25 %). The non sericin components consist mainly of carbohydrates, salt, waxes (Mondal et al., 2007\[[@R29]\]), and some flavonoids derivatives. The main flavonoids are quercetin glycosides (quercetin 5-O-beta-D-glucoside, quercetin 7-O-beta-D-glucoside, and quercetin 4-O-beta-D-glucoside) with two kaempferol glycosides (kaempferol 5-O-beta-D-glucoside and kaempferol 7-O-beta-D-glucoside) (Kurioka and Yamazaki, 2002\[[@R21]\]). Sericin and fibroin are rich sources of amino acids (Schroeder et al., 1955\[[@R37]\]), which can play an important role in myocardial protection (Julia et al., 1990\[[@R16]\]), since shielding effect of amino acids has already been reported to significantly improve the recovery of cardiac function (Shug et al., 1994\[[@R40]\]). However, flavonoids act as scavengers of reactive oxygen species (Haenen et al., 1993\[[@R12]\]). Mahmood and colleagues (2013\[[@R26]\]) have suggested the potent antioxidative activity of *B. mori* cocoon is mainly due to rich source of free amino acids and flavonoid compounds present in them (Kurioka and Yamazaki, 2002\[[@R21]\]).

Most of the previous studies are either on alcoholic extract or on crude *B. mori*, whereas, according to official Unani Pharmacopoeia and other literature of traditional system of medicine aqueous decoction is used in most of the Unani formulations. Therefore, the purpose of the present study was to elucidate the potential of standardized *B. mori* aqueous extract (BMAE) against DOX induced cardiomyopathy in rats.

Materials and Methods
=====================

Experimental animals
--------------------

Adult male wistar albino rats (10- 12 week old), having body weight of 150-200 g, were used. Animals were acclimatized and housed under controlled conditions of illumination (12 h light/dark cycles) with temperature of 20-25 °C and relative humidity of 30 + 5 %. Standard pellet diet (Ashirwad Rat Feed, Chandigarh, India) and water *ad libitum* were provided to the animals throughout the study period. The study was approved by the Institutional Animal Ethics Committee (CPCSEA registration no 173/CPCSEA) of Jamia Hamdard, New Delhi.

Drugs and chemicals
-------------------

*B. mori* was procured from the local drug market and identified by Dr. A. Ahmad, Department of Ilmul Advia, Faculty of Medicine, Hamdard University, New Delhi. A voucher specimen was deposited in the herbarium of the Bioactive Natural Product Laboratory (Specimen no-54/BM/BNPL/ 2012). DOX was obtained as Adrim injection (Dabur Pharmaceuticals, India) whereas desferrioxamine as Desferal injection (Novartis Pharmaceuticals, Switzerland). All the other chemicals used were of analytical grade.

Preparation of extract
----------------------

The aqueous extract of *Bombyx mori* (BMAE) was prepared similar to the method used for development of traditional formulations. In brief, the cocoons were sliced into small pieces and 200 g of it was placed in round bottom flask of 5 L capacity. The extraction was carried out using reflux condenser and double distilled water (DDW) (3 L) as solvent for two hours on water bath. It was kept aside overnight with occasional shaking and press filtered using muslin cloth. The residue left was washed with fresh solvent (DDW). The extract and washings were pooled and concentrated in rota-vapour, followed by drying in lyophilizer (extractive value 5.66 % w/w) to get free flowing powder. It was stored in cool place (4 °C) till analysis and bioactivity.

Metabolic profiling of extract by using UPLC-MS
-----------------------------------------------

The freeze dried powdered of BMAE was dissolved in LCMS grade acetonitrile and water (100 µg mL^-1^) and filtered. The constituents were analyzed on a Water's ACQUITY UPLC^TM^ system (Serial No\# F09 UPB 920M; Model Code\# UPB; Waters Corp., MA, USA) equipped with a binary solvent delivery system, an auto-sampler, column manager and a tunable MS detector (Serial No\# JAA 272; SYNAPT; WATERS, Manchester, UK). Chromatographic separation was performed on a Water's ACQUITY UPLC^TM^ BEH C18 (100.0 mm x 2.1 mm; 1.7 µm) column at 40 ± 5 °C. The UPLC analysis was done using water: acetonitrile (90:10; v/v), as solvent system in gradient elution. The flow rate of the mobile phase was kept at 0.35 mL min^-1^ and 10 µL of sample solution was injected in each run. The total chromatographic run time was 30 min. The column and auto-sampler were maintained at 40 ± 5 and 25 ± 5 °C, respectively whereas the pressure of the system was set to 15000 psi.

Determination of free amino acids by using HPLC-FLD
---------------------------------------------------

Determination of amino acids as their respective 6-aminoquinolyl-**N**-hydroxysuccinimidyl carbamate (AQC) derivatives were successfully applied for assessing free amino acid levels in BMAE based on the **Waters** AccQ.Tag™ method for high performance liquid chromatography (HPLC) (Kabelová et al., 2009\[[@R18]\]).

Determination of in vitro anti-oxidant potential
------------------------------------------------

Superoxide radical scavenging and hydrogen peroxide scavenging potentials of BMAE were determined as per the methods reported by Amir and colleagues (2011\[[@R4]\]) in the concentration range of 5.0-35 µg mL^-1^ using ascorbic acid as standard.

In vivo cardioprotective activity
---------------------------------

### Animals and dosing schedule

The animals were housed in polypropylene cages (size 40 x 25 x 16 cm) in groups of six rats per cage. These were allowed to acclimatize for one week before the experiments and were given free access to standard laboratory animal diet and water *ad libitum*. After acclimatization rats were randomly assigned into five groups of six animals each. Group 1 (vehicle control), rats were treated with 0.5 % carboxy methyl cellulose (CMC) in normal saline (2 mL/Kg/p.o./day) for 30 days. Group 2 (pathogenic control; DOX), received 0.5 % CMC in normal saline (2 mL/Kg/p.o./day) for 30 days along with doxorubicin (20 mg/Kg, single i.p. injection) on 31^st^ day. Group 3 (BMAE 30) animals were administered with BMAE (30 mg/Kg/ p.o./day) for 30 days and DOX (20 mg/Kg, single i.p. injection) on 31^st^ day. Similarly, group 4 (BMAE 60) animals were administered with BMAE (60 mg/Kg/p.o./day) for 30 days and DOX (20 mg/Kg, single i.p. injection) on 31^st^ day. Group 5 (DFX) was given desferrioxamine (50 mg/Kg/i.v. injection /day) for 30 days with DOX (20 mg/Kg, single i.p. injection) on 31^st^ day (Ayla et al., 2011\[[@R5]\]; Sharma et al., 2011\[[@R39]\]). At the end of treatment (i.e. 31^st^ day), animals were fasted overnight (12 h) and blood samples were collected from retro-orbital plexus under mild ether anesthesia for separation of serum. Further, animals were sacrificed by cervical dislocation and heart was excised, which was stored at -80 °C for histopathology and biochemical estimation.

### Biochemical estimation

CK-MB and LDH activity (Reckon Diagnostics Pvt. Ltd, India) (Lum and Gambino, 1974\[[@R25]\]), IL-6 (Ray Biotech) (Helle et al., 1991\[[@R13]\]), TNF-α (e-Bioscience, Inc., USA) (Lehmann et al., 2008\[[@R22]\]) and protein (Lowry et al., 1951\[[@R24]\]) were measured in serum as per standard methods. Similarly, caspase-3 was measured (Bio Vision, Inc., USA) (Jaeschke et al., 1998\[[@R15]\]). Lipid peroxidation (Iqbal et al., 2008\[[@R14]\]) and protein (Lowry et al., 1951\[[@R24]\]) were estimated in heart tissue homogenate as per the standard protocol.

### Histopathological examination

The heart tissues were fixed in 10 % formalin and sections were prepared with thickness up to 5.0 µm. These were stained with hematoxylin and eosin for histopathological evaluation of heart sections and were carried out by a pathologist unaware of groups (Belur et al., 1990\[[@R6]\]).

### Statistical analysis

The data is expressed as mean ± SD. Statistical differences between means were determined by one-way analysis of variance (ANOVA), followed by Dunnett's t test. The values of P\<0.05 were considered as significant.

Results
=======

Quality control of BMAE
-----------------------

The extraction of *B. mori* as per the traditional method resulted in 5.66 % w/w of BMAE, which was further subjected to the quality control analysis. The metabolic profiling of BMAE by UPLC-qTOF-MS followed by tentative structure assignment using m/z and literature showed identification and separation of twenty eight constituents out of which quercetin 7-*O*-ß-D-glucoside, kaempferol 7-*O*-ß-D-glucopyranoside, coumaric acid glucoside, 2-hydroxy-nonade-canoic acid, 9,12-dihydroxy stearic acid were present in highest amount as compared to other constituents (Table 1[(Tab. 1)](#T1){ref-type="fig"}). The amino acid profiling by HPLC-FLD revealed presence of 17 amino acids v.i.z. proline, cysteine, methionine, aspartic acid, serine, alanine, lysine, leucine, histidine, threonine, glycine, arginine, tyrosine, valine, isoleucine and phenylalanine (Figure 1[(Fig. 1)](#F1){ref-type="fig"}). The content of cysteine, methionine and proline were found highest, whereas isoleucine and tyrosine were found lowest (Table 2[(Tab. 2)](#T2){ref-type="fig"}).

The BMAE showed a concentration-dependent antioxidant activity by inhibiting super oxide radical with an IC~50~ value of 30.6 µg mL^-1^, whereas IC~50~ value of ascorbic acid was found to be 14.9 µg mL^-1^ (Figure 2B[(Fig. 2)](#F2){ref-type="fig"}). Similarly, results of hydrogen peroxide scavenging activity for BMAE showed dose dependent activity between 5.0 - 35 µg mL^1^ with IC~50~ value at 14.05 µg mL^-1^ and ascorbic acid at 6.77 µg mL^-1^ (Figure 2A[(Fig. 2)](#F2){ref-type="fig"}).

Biochemical estimation
----------------------

There was marked elevation in the mean serum CK-MB level of DOX treated group as compared to control group (P\<0.01 vs CNT). Treatment with BMAE and DFX showed significant reduction (P\<0.01 vs DOX) in the CK-MB levels when compared to toxicant group (Table 3[(Tab. 3)](#T3){ref-type="fig"}). Results of LDH estimation showed significant (P\<0.01 vs CNT) elevation in the mean serum LDH level of DOX treated group in comparison to control group. Whereas, groups treated with BMAE and DFX showed significant reduction (P\<0.01 vs DOX) in mean serum LDH level as compared to toxicant group (Table 2[(Tab. 2)](#T2){ref-type="fig"}). The mean tissue MDA and caspase-3 levels (nmol mg-1 of protein) of DOX treated group were found significantly higher (P\<0.01 vs CNT), which were significantly reversed after treatment with BMAE and DFX (P\<0.01 vs DOX) (Figure 3[(Fig. 3)](#F3){ref-type="fig"}). DOX treated group also showed significant elevation (P\<0.01 vs CNT) in serum TNF-alpha, IL-6 and tissue caspase-3 levels as compared to control group. Whereas, DFX and BMAE treated groups at 30 and 60 mg kg^-1^ showed significant reversal (P\<0.01) to DOX toxicity of TNF-alpha, IL-6 as well as caspase-3 levels (Table 4[(Tab. 4)](#T4){ref-type="fig"}).

Histopathology
--------------

The cardiac tissue samples belonging to CNT, DOX, BMAE and DFX treated groups were examined with special reference to myocardial fiber integrity and histological evidence of DOX induced cardiac damage. CNT group showed normal myocardial structure, whereas DOX treated group showed disarray of myocardial cells with small and large vacuolar myopathy. However, there was no evidence of necrosis of the myocardium. The heart samples from the BMAE treated group at 30 and 60 mg Kg^-1^ day^-1^ as well as STD group showed a normal myocardium with no evidence of vacuolar myopathy (Figure 4[(Fig. 4)](#F4){ref-type="fig"}).

Discussion
==========

Doxorubicin (DOX) is an excellent antineoplastic agent for treating several types of hematological and solid malignancies (Shah et al., 2012\[[@R38]\]; Pathan et al., 2012\[[@R34]\]). Previously, DOX related cardiotoxicities are well documented; DOX is metabolically reduced to highly reactive free radicals, which generates superoxide and hydrogen peroxide. These highly toxic free radicals cause lipid peroxidation, inhibition of long chain fatty acids (Khan et al., 2014\[[@R19]\]; Nohl et al., 1998\[[@R33]\]) and cause damage to cellular components.

The aqueous extract/decoction of *Bombyx mori* has been used since long in the Unani System of Medicine as a part of many of such formulations for the treatment of heart diseases. Some of the studies have already been reported earlier on alcoholic extract and on cocoon as such (crude) for its hypolipidemic potential (Mahmood et al., 2013\[[@R26]\]), cardioprotective activity against DOX induced cardiotoxicity and isoprenaline induced myocardial necrosis (Kumar et al., 2013\[[@R20]\]; Nazmi et al., 2013\[[@R32]\]). However, effect of *B. mori* aqueous extract in prevention of cardiac toxicity is yet to be established. Hence, we envisaged to evaluate the cardioprotective potential of the standardized aqueous extract (freeze dried and powdered) for scientific validation of its use in traditional formulations as a major cardioprotective agent.

In the present investigation DOX produced a significant cardiotoxicity at the acute dose of (20 mg/Kg/i.p./single dose) in male Wistar rats as evident by increased levels of serum LDH and CK-MB whereas reduced MDA and caspase-3 levels in cardiac tissue. The results were further supported by histopathological studies of cardiac tissue, which is consistent with previous work (Ayla et al., 2011\[[@R5]\]; Mokni et al., 2012\[[@R28]\]) in which significant acute cardiotoxicity was reported in rats 24 h after DOX treatment i.e. 20 mg/Kg/ i.p./single dose. In the present study, pretreatment with *B. mori* aqueous extract (BMAE) at a dose of 30 and 60 mg/Kg significantly suppressed cardiac toxicity induced by DOX. The protective effect of BMAE against DOX-induced cardiovascular damage is due to its prominent anti-oxidant activity.

Increased level of different enzymes is possibly a reflection that the DOX treatment induces cardiac tissue damage, whereas LDH and CK-MB are relatively specific for myocardial damage (Yagmurca et al., 2003\[[@R43]\]). In the present study, marked elevation in the activities of LDH and CK-MB in the serum of doxorubicin intoxicated rats were observed (P\<0.01), which are in agreement with Abdel-Sattar and colleagues (2012\[[@R1]\]). Shah and colleagues (2012\[[@R38]\]) who reported significant increase in serum LDH and CK-MB level after a single dose of doxorubicin 20 mg/Kg. The rise in serum LDH and CK-MB level suggests an increased leakage of this enzyme from cardiac tissues into the systemic circulation after DOX treatment. However, treatment of rats with BMAE (30 and 60 mg/Kg), LDH and CK-MB level was decreased to a level near to that of the control group. This protective effect could be attributed due to the antioxidant property and presence of various amino acids and flavonoids in*B. mori*. Significant increase in MDA content (an index of lipid peroxidation) in cardiac tissues, of DOX induced rats has been observed, which correlates with the previous studies (Fard et al., 2010\[[@R9]\]; Hadi et al., 2012\[[@R11]\]; Abdel-Wahab et al., 2003\[[@R2]\]). The pretreatment with BMAE decrease the oxidative stress and lowers the level of MDA in cardiac tissues indicating decrease in oxidative stress and lipid peroxidation.

Free radicals may directly disrupt lipid membranes and they may also mediate the activation of genes for some pro-inflammatory cytokines (TNF-α, IL-1, IL-6) (Schreck and Baeuerle, 1991\[[@R36]\]). In our study, rise in the levels of inflammatory cytokine (TNF-α, IL-6) (P\<0.01) was found in DOX treated group as compared to control group which are in agreement with that of previously reported work (Elbaky et al., 2010\[[@R8]\]; Bien et al., 2007\[[@R7]\]; Moore et al., 2001\[[@R30]\]). Pretreatment with BMAE, significantly lowered (P\<0.01) the levels of TNF-α and IL-6, which may be due to its antioxidant property.

DOX treatment increased the production of free radicals and activates the caspase-3, a major effector caspase that plays a critical role in the apoptotic cascade. In the present investigation increase in the caspase activity in cardiac tissue of DOX treated rats was observed which supports the results of Yang and colleagues (2006\[[@R44]\]), Ueno and colleagues (2006\[[@R41]\]), who reported increase in caspase-3 activity in DOX induced cardio-toxicity. Pretreatment with BMAE before DOX administration lowers the cardiac caspase-3 levels by inhibiting apoptosis.

The results of present investigations validated scientifically its use in various Unani formulations such as Khamira Abresham Hakim Arshadwala, Khamira Abresham Sada etc. which is in agreement with earlier reports on Khamira's for cardioprotection (Goyal et al., 2010\[[@R10]\]).

Histological observations further confirm the DOX induced disarray of myocardial fibers and vacuolization. These deleterious changes seem resistent on pretreatment with BMAE. These observations provide convincing microscopic evidences regarding the cardioprotective potential of BMAE. Parameters investigated here indicated that aqueous extract of BM is potent in alleviating DOX induced myocardial damage and amelioration of heart vacuolation. The observed results have been attributed to its free radicals scavenging capability, and to regulate the generation of inflammatory mediators.

Conclusion
==========

On the basis of these findings it can be concluded that aqueous extract of BM has cardioprotective potential. This may be due to high content of amino acid and flavonoid in BMAE. The mechanism of cardioprotection may involve reduction in apoptotic factor (caspase-3 and TNF-alpha), oxidative stress (MDA), cardiac enzyme activity (CK-MB and LDH) as well as proinflammatory (interleukin-6) marker.
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